| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDH17 |
| Uniprot No | Q12864 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-131aa |
| 氨基酸序列 | EGKFSGPLKPMTFSIYEGQEPSQIIFQFKANPPAVTFELTGETDNIFVIE REGLLYYNRALDRETRSTHNLQVAALDANGIIVEGPVPITIEVKDINDNR PTFLQSKY |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDH17重组蛋白的3篇代表性文献及其摘要概括(文献信息为模拟示例，建议通过学术数据库获取全文)：
---
1. **标题**：*Structural insights into CDH17 extracellular domains and their role in cell adhesion*
**作者**：Dong Y, et al.
**摘要**：通过重组表达CDH17的胞外结构域，解析其晶体结构，揭示了CDH17在钙离子依赖的细胞间黏附中的分子机制，为靶向治疗提供结构基础。
---
2. **标题**：*CDH17 recombinant protein as a diagnostic marker for metastatic colorectal cancer*
**作者**：Bulle A, et al.
**摘要**：利用重组CDH17蛋白开发新型ELISA检测方法，证实其在结直肠癌患者血清中的高表达与转移风险显著相关，具有潜在临床诊断价值。
---
3. **标题**：*Targeting CDH17 with recombinant immunotoxins in gastric cancer models*
**作者**：Huang L, et al.
**摘要**：构建CDH17重组蛋白偶联的免疫毒素，体外实验显示其可特异性结合胃癌细胞并诱导凋亡，提示CDH17作为治疗靶点的可行性。
---
**提示**：实际文献可通过PubMed或Google Scholar搜索关键词“CDH17 recombinant protein”获取，部分研究可能涉及重组表达、功能验证或治疗应用。
CDH17 (Cadherin-17), also known as liver-intestine cadherin (LI-cadherin), is a calcium-dependent cell adhesion protein belonging to the cadherin superfamily. Unlike classical cadherins that mediate cell-cell adhesion in epithelial tissues, CDH17 is primarily expressed in the gastrointestinal tract, particularly in the liver, pancreas, and intestinal epithelium. It plays a critical role in maintaining tissue architecture and regulating cellular signaling pathways. Structurally, CDH17 contains seven extracellular cadherin repeats, a transmembrane domain, and a short cytoplasmic tail that lacks the conserved catenin-binding motifs found in other cadherins. This unique feature suggests distinct regulatory mechanisms for its adhesive and signaling functions.
Recombinant CDH17 protein is engineered in vitro using expression systems such as mammalian cells or bacteria to produce purified, functional protein for research applications. Its production enables the study of CDH17’s biological roles, including its involvement in cancer progression. CDH17 is overexpressed in gastrointestinal cancers (e.g., gastric, colorectal, hepatocellular carcinomas) and has been implicated in tumor metastasis, making it a potential diagnostic marker or therapeutic target. Recombinant CDH17 facilitates investigations into its interactions with ligands like β-catenin or matrix metalloproteinases (MMPs), which are linked to Wnt signaling activation and extracellular matrix remodeling.
Additionally, recombinant CDH17 is used to develop antibodies, screen inhibitory compounds, and model tissue-specific adhesion mechanisms. Its role in maintaining intestinal barrier integrity and regulating cell proliferation further highlights its relevance in both physiological and pathological contexts. Despite its promise, the precise molecular pathways governed by CDH17 remain under exploration, necessitating continued research using recombinant tools to unravel its dual functions in health and disease.
×
